---
title: "PHGE.US (PHGE.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/PHGE.US/news.md"
symbol: "PHGE.US"
name: "PHGE.US"
parent: "https://longbridge.com/en/quote/PHGE.US.md"
datetime: "2026-05-20T22:53:27.270Z"
locales:
  - [en](https://longbridge.com/en/quote/PHGE.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/PHGE.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/PHGE.US/news.md)
---

# PHGE.US (PHGE.US) — Related News

### [12 Health Care Stocks Moving In Wednesday's After-Market Session](https://longbridge.com/en/news/287123139.md)
*2026-05-20T21:05:59.000Z*
> In Wednesday's after-market session, Liminatus Pharma (LIMN) surged 24.1% to $0.23, while BiomX (PHGE) rose 12.33% to $0

### [BiomX Inc. 1Q 2026: Net income $(19.14M), EPS $(7.38) — 10-Q Summary](https://longbridge.com/en/news/287120250.md)
*2026-05-20T21:01:01.000Z*
> BiomX Inc. reported a net loss of $19.14M for Q1 2026, up from $7.66M in Q1 2025, as it shifts focus from biopharma to d

### [BiomX | 10-Q: FY2026 Q1 Revenue: USD 0](https://longbridge.com/en/news/287118860.md)
*2026-05-20T20:55:40.000Z*
### [BiomX Q1 net loss widens to USD 19.14 million; operating loss narrows to USD 1.3 million](https://longbridge.com/en/news/287118746.md)
*2026-05-20T20:53:38.000Z*
> BiomX reported a Q1 net loss of USD 19.14 million, up from USD 7.66 million a year prior, with a loss per share of USD 7

### [U.S. stock market midday update: BiomX up 22.54% with increased trading volume, market sentiment is high but volatility should be monitored](https://longbridge.com/en/news/287087469.md)
*2026-05-20T14:58:02.000Z*
> BiomX rose 22.54%; Immunovant rose 34.16%, with a trading volume of USD 318 million; Amgen fell 0.35%, with a trading vo

### [12 Health Care Stocks Moving In Wednesday's Pre-Market Session](https://longbridge.com/en/news/287062638.md)
*2026-05-20T12:06:04.000Z*
> In Wednesday's pre-market session, Silexion Therapeutics surged 147.2% to $0.67, while Jupiter Neurosciences rose 106.25

### [Pre-market hot trades in US stocks: BiomX up 36.84% in pre-market; C3is down 12.47% in pre-market](https://longbridge.com/en/news/287038640.md)
*2026-05-20T09:27:31.000Z*
> BiomX pre-market rose 36.84%; C3is pre-market fell 12.47%; Micware pre-market rose 302.73%; Silexion Therapeutics pre-ma

### [BiomX Delays Quarterly Report Amid Strategic Shift](https://longbridge.com/en/news/286624580.md)
*2026-05-15T23:38:30.000Z*
> BiomX has announced a delay in filing its Quarterly Report for the period ended March 31, 2026, due to the need for addi

### [BiomX Reinvents Itself as Diversified Defense Technology Platform](https://longbridge.com/en/news/285279912.md)
*2026-05-05T23:04:40.000Z*
> BiomX has undergone a strategic overhaul, exiting its legacy biotech operations and transitioning to a diversified defen

### [Pre-market hot trades in US stocks: BiomX up 8.90% in pre-market, with clear capital flow, market sentiment triggers volatility attention](https://longbridge.com/en/news/284750734.md)
*2026-04-30T10:52:30.000Z*
> BiomX pre-market up 8.90%; Abits pre-market up 41.44%; Everspin Technologies pre-market up 35.78%; Akanda pre-market up